Even after rising 29% this past week, Seres Therapeutics (NASDAQ:MCRB) shareholders are still down 84% over the past three years [Yahoo! Finance]
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: Yahoo! Finance
But only the myopic could ignore the astounding decline over three years. To wit, the share price sky-dived 84% in that time. So we're relieved for long term holders to see a bit of uplift. Of course the real question is whether the business can sustain a turnaround. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson. The recent uptick of 29% could be a positive sign of things to come, so let's take a look at historical fundamentals. View our latest analysis for Seres Therapeutics Because Seres Therapeutics made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit. Over three years, Seres Therapeut
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB) [Yahoo! Finance]Yahoo! Finance
- 2024 Microbiome Market Trends Report: Competitive Environment Analysis, Digital Platform and Marketing Strategies, and AI Adoption in the Industry [Yahoo! Finance]Yahoo! Finance
- Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $10.00 price target on the stock.MarketBeat
- Human Microbiome Market Projected to Surpass to $3 Billion by 2032 with DuPont, Evelo Bio, Finch Therapeutics, Ginkgo Bioworks, Seres Therapeutics, AOBiome, Astarte Medical, Axial Biotherapeutics [Yahoo! Finance]Yahoo! Finance
MCRB
Earnings
- 8/13/24 - Beat
MCRB
Sec Filings
- 8/26/24 - Form DEFM14A
- 8/19/24 - Form 4
- 8/19/24 - Form 4
- MCRB's page on the SEC website